{"id":"https://openalex.org/W2806568072","doi":"https://doi.org/10.1212/wnl.90.15_supplement.p5.270","title":"Analysis of Psychiatric Treatment-Emergent Adverse Events (TEAEs) in Two Phase III Conversion-to-Eslicarbazepine Acetate (ESL) Monotherapy Trials (P5.270)","display_name":"Analysis of Psychiatric Treatment-Emergent Adverse Events (TEAEs) in Two Phase III Conversion-to-Eslicarbazepine Acetate (ESL) Monotherapy Trials (P5.270)","publication_year":2018,"publication_date":"2018-04-10","ids":{"openalex":"https://openalex.org/W2806568072","doi":"https://doi.org/10.1212/wnl.90.15_supplement.p5.270","mag":"2806568072"},"language":"en","primary_location":{"id":"doi:10.1212/wnl.90.15_supplement.p5.270","doi":"https://doi.org/10.1212/wnl.90.15_supplement.p5.270","is_oa":false,"landing_page_url":"http://dx.doi.org/10.1212/wnl.90.15_supplement.p5.270","pdf_url":null,"source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5080677331","display_name":"Cynthia L. Harden","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Cynthia Harden","raw_affiliation_strings":["Mount Sinai Downtown - Union Square New York NY United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mount Sinai Downtown - Union Square New York NY United States","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018402892","display_name":"Jay A. Salpekar","orcid":"https://orcid.org/0000-0002-6023-9430","observed_orcids":["https://orcid.org/0000-0002-6023-9430"]},"institutions":[{"id":"https://openalex.org/I1298154867","display_name":"Kennedy Krieger Institute","ror":"https://ror.org/05q6tgt32","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I1298154867"]},{"id":"https://openalex.org/I145311948","display_name":"Johns Hopkins University","ror":"https://ror.org/00za53h95","country_code":"US","type":"education","lineage":["https://openalex.org/I145311948"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jay Salpekar","raw_affiliation_strings":["Kennedy Krieger Institute, Johns Hopkins University, School of Medicine Baltimore MD United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Kennedy Krieger Institute, Johns Hopkins University, School of Medicine Baltimore MD United States","institution_ids":["https://openalex.org/I1298154867","https://openalex.org/I145311948"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088890091","display_name":"David W. Loring","orcid":"https://orcid.org/0000-0003-2497-1074","observed_orcids":["https://orcid.org/0000-0003-2497-1074"]},"institutions":[{"id":"https://openalex.org/I150468666","display_name":"Emory University","ror":"https://ror.org/03czfpz43","country_code":"US","type":"education","lineage":["https://openalex.org/I150468666"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David Loring","raw_affiliation_strings":["Emory University Atlanta GA United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Emory University Atlanta GA United States","institution_ids":["https://openalex.org/I150468666"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084941652","display_name":"Todd Grinnell","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210122020","display_name":"Sunovion (United States)","ror":"https://ror.org/030zc7t66","country_code":"US","type":"company","lineage":["https://openalex.org/I4210122020"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Todd Grinnell","raw_affiliation_strings":["Sunovion Pharmaceuticals Inc. Marlborough MA United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sunovion Pharmaceuticals Inc. Marlborough MA United States","institution_ids":["https://openalex.org/I4210122020"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101974561","display_name":"David Cantu","orcid":"https://orcid.org/0000-0003-3174-0530","observed_orcids":["https://orcid.org/0000-0003-3174-0530"]},"institutions":[{"id":"https://openalex.org/I4210122020","display_name":"Sunovion (United States)","ror":"https://ror.org/030zc7t66","country_code":"US","type":"company","lineage":["https://openalex.org/I4210122020"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David Cantu","raw_affiliation_strings":["Sunovion Pharmaceuticals Inc. Marlborough MA United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sunovion Pharmaceuticals Inc. Marlborough MA United States","institution_ids":["https://openalex.org/I4210122020"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071608501","display_name":"Hailong Cheng","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210122020","display_name":"Sunovion (United States)","ror":"https://ror.org/030zc7t66","country_code":"US","type":"company","lineage":["https://openalex.org/I4210122020"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hailong Cheng","raw_affiliation_strings":["Sunovion Pharmaceuticals Inc. Marlborough MA United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sunovion Pharmaceuticals Inc. Marlborough MA United States","institution_ids":["https://openalex.org/I4210122020"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5103238393","display_name":"David E. Blum","orcid":"https://orcid.org/0000-0002-1150-8331","observed_orcids":["https://orcid.org/0000-0002-1150-8331"]},"institutions":[{"id":"https://openalex.org/I4210122020","display_name":"Sunovion (United States)","ror":"https://ror.org/030zc7t66","country_code":"US","type":"company","lineage":["https://openalex.org/I4210122020"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David Blum","raw_affiliation_strings":["Sunovion Pharmaceuticals Inc. Marlborough MA United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sunovion Pharmaceuticals Inc. Marlborough MA United States","institution_ids":["https://openalex.org/I4210122020"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":4,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.07451722,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"90","issue":"15_supplement","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10094","display_name":"Epilepsy research and treatment","score":0.9336000084877014,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10094","display_name":"Epilepsy research and treatment","score":0.9336000084877014,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.007799999788403511,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12229","display_name":"Pharmacological Effects and Toxicity Studies","score":0.006399999838322401,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/eslicarbazepine-acetate","display_name":"eslicarbazepine acetate","score":0.984000027179718},{"id":"https://openalex.org/keywords/treatment-emergent-adverse-events","display_name":"treatment-emergent adverse events","score":0.9079999923706055},{"id":"https://openalex.org/keywords/psychiatric-adverse-events","display_name":"psychiatric adverse events","score":0.9919999837875366},{"id":"https://openalex.org/keywords/epilepsy","display_name":"epilepsy","score":0.5569999814033508},{"id":"https://openalex.org/keywords/antiepileptic-drugs","display_name":"antiepileptic drugs","score":0.8569999933242798},{"id":"https://openalex.org/keywords/adverse-event-frequency","display_name":"adverse event frequency","score":0.7179999947547913}],"concepts":[{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.6912183165550232},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5447545647621155},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.44959723949432373},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.32133209705352783}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1212/wnl.90.15_supplement.p5.270","doi":"https://doi.org/10.1212/wnl.90.15_supplement.p5.270","is_oa":false,"landing_page_url":"http://dx.doi.org/10.1212/wnl.90.15_supplement.p5.270","pdf_url":null,"source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"sustainable_development_goals_aurora":[{"score":0.7900000214576721,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2794846120","https://openalex.org/W4389449912","https://openalex.org/W4288968146","https://openalex.org/W2806079983","https://openalex.org/W4389441721","https://openalex.org/W2805579729","https://openalex.org/W3215703293","https://openalex.org/W4389445225","https://openalex.org/W1969318397","https://openalex.org/W2590296308"],"abstract_inverted_index":{"Objective:":[0],"To":[1],"examine":[2],"the":[3,137,148,174],"frequency":[4],"of":[5,39,188,239,280,286],"psychiatric":[6,20,178,181],"TEAEs":[7,34,132,182,215,235,272,282],"in":[8,37,47,67,186,208,220,259,277,345],"two":[9,56],"conversion-to-ESL":[10,48,61,262],"monotherapy":[11,49,62,263],"trials.":[12,50],"Background:":[13],"Antiepileptic":[14],"drugs":[15],"(AEDs)":[16],"may":[17],"cause":[18],"adverse":[19],"effects.":[21],"ESL":[22,88,116,118,121,165,246,250,296],"is":[23],"a":[24,329,372,395,418,441],"once-daily":[25],"oral":[26],"AED":[27],"for":[28,94,126,140,325,349,368,391,414,437],"partial-onset":[29],"(focal)":[30],"seizures":[31],"(POS).":[32],"Psychiatric":[33,129,155,190,214,254],"were":[35,53,84,133,173,183,203,231,242,266,273,291],"infrequent":[36],"trials":[38,63],"adjunctive":[40],"ESL,":[41],"but":[42],"have":[43],"not":[44],"been":[45],"evaluated":[46],"Design/Methods:":[51],"Data":[52],"pooled":[54,108],"from":[55,317,360],"Phase":[57,260],"III":[58,261],"randomized,":[59],"dose-blind,":[60],"(093\u2013045":[64],"and":[65,130,170,201,228,236,283,289,293,351],"\u2212046)":[66],"adults":[68],"(16\u250070":[69],"years)":[70],"with":[71,245,337,380,403,426,449],"POS":[72],"uncontrolled":[73],"by":[74],"1\u20132":[75],"AEDs.":[76],"Following":[77],"an":[78,346],"8-week":[79],"baseline":[80,102],"period,":[81],"eligible":[82],"patients":[83,113,222],"randomized":[85,112],"2:1":[86],"to":[87,217,295,309],"1600mg":[89,251],"or":[90,197,275,334,377,400,423,446],"1200mg":[91,247],"once":[92],"daily":[93],"18":[95],"weeks":[96,98,101,105],"(2":[97],"titration,":[99],"6":[100],"AED-taper,":[103],"10":[104],"monotherapy).":[106],"The":[107],"intent-to-treat":[109],"population":[110],"(all":[111],"receiving":[114],"\u22651":[115],"dose;":[117],"1600mg,":[119,163,212,224],"n=242;":[120],"1200mg,":[122,166],"n=123)":[123],"was":[124,145,158,193,257],"used":[125],"all":[127],"analyses.":[128],"depression/suicidality":[131,281],"identified":[134],"(categorized":[135],"using":[136,147],"Medical":[138],"Dictionary":[139],"Regulatory":[141],"Activities,":[142],"v13.1).":[143],"Suicidality":[144],"assessed":[146],"Columbia-Suicide":[149],"Severity":[150],"Rating":[151],"Scale":[152],"(C-SSRS).":[153],"Results:":[154],"TEAE":[156,191,255],"incidence":[157,256],"similar":[159,267],"between":[160,268],"doses":[161],"(ESL":[162,211,223],"15.3%;":[164],"17.9%).":[167],"Insomnia":[168],"(4.9%)":[169],"anxiety":[171,229],"(3.6%)":[172],"most":[175,232,271],"frequently":[176],"reported":[177,185,204],"TEAEs;":[179],"other":[180,335,378,401,424,447],"each":[184],"<2%":[187],"patients.":[189],"severity":[192],"generally":[194],"mild":[195,274],"(57.6%)":[196],"moderate":[198,276],"(35.6%).":[199],"Anxiety":[200],"depression":[202,226],"as":[205],"serious":[206],"AEs":[207],"one":[209],"patient":[210],"0.4%).":[213],"leading":[216],"discontinuation":[218],"occurred":[219],"six":[221],"2.5%);":[225],"(1.2%)":[227],"(0.8%)":[230],"frequent.":[233],"Depression/suicidality":[234],"C-SSRS":[237,284],"ratings":[238,285],"suicidal":[240,287],"ideation/behavior":[241],"more":[243],"frequent":[244],"(8.9%/4.1%)":[248],"versus":[249],"(5.0%/1.2%).":[252],"Conclusions:":[253],"<18%":[258],"trials;":[264],"incidences":[265],"dose":[269],"groups;":[270],"severity.":[278],"Incidences":[279],"ideation":[288],"behavior":[290],"low":[292],"unrelated":[294],"dose.":[297],"Study":[298],"Supported":[299],"by:":[300],"Sunovion":[301,382,405,428,451],"Pharmaceuticals":[302,383,406,429,452],"Inc.":[303,384,407,430,453],"Disclosure:":[304],"Dr":[305],"Harden":[306],"has":[307,313,321,341,356,364,387,410,433],"nothing":[308],"disclose.":[310],"Dr.":[311,319,339,354,362,385,408,431],"Salpekar":[312],"received":[314,322,342,357,365,388,411,434],"research":[315,358],"support":[316,359],"Lundbeck.":[318],"Loring":[320,340,355],"personal":[323,343,366,389,412,435],"compensation":[324,344,367,390,413,436],"consulting,":[326,369,392,415,438],"serving":[327,370,393,416,439],"on":[328,371,394,417,440],"scientific":[330,373,396,419,442],"advisory":[331,374,397,420,443],"board,":[332,375,398,421,444],"speaking,":[333,376,399,422,445],"activities":[336,379,402,425,448],"NeuroPace.":[338],"editorial":[347],"capacity":[348],"Epilepsia":[350],"Neuropsychology":[352],"Review.":[353],"Medtronic.":[361],"Grinnell":[363],"Employment:":[381,404,427,450],"Cantu":[386],"Cheng":[409],"Blum":[432]},"counts_by_year":[],"updated_date":"2026-10-26T11:51:55.731654","created_date":"2018-06-13T00:00:00"}